Periostin antisense oligonucleotide prevents hepatic steatosis and fibrosis in a mouse model of non-alcoholic steatohepatitis.
Tomoki KobayashiKeishi KannoPhuong Thao NguyenAkiko SugiyamaAkihiro KawaharaYuichiro OtaniNobusuke KishikawaMasanori ItoSusumu TazumaPublished in: Journal of gastroenterology and hepatology (2020)
Periostin-targeting ASO is a potential therapeutic approach for the efficient treatment of hepatic steatosis and fibrosis in NASH.